Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million aggregate principal amount of its 1.250% convertible senior notes due 2025.

Headquartered in Fort Myers, Florida, NeoGenomics operates a network of cancer-focused testing laboratories in the United States as well as in Switzerland and Singapore.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jeffrey Gould and associates Scott A. Blumenkranz and Joseph G. Marano. The tax team included partner Michael Farber and associate Yixuan Long. Partner Frank J. Azzopardi and associates Christopher C. Woller and Yifu Chen provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

 
Copy link to share post